Daniel Glassman

Consultant Oncoplastic Breast Surgeon | Clinical Lead @MidYorkshireNHS | @spirehealthcare Spire Leeds, Spire Methley Park | Breast surgeon Leeds Wakefield

[Daniel Glassman @GlassmanDS]

@footballontnt @Charlie_Popeye Well said Declan Rice

[Daniel Glassman @GlassmanDS]

@Arsenal Champions ❤️🔥🔥🔥

[Daniel Glassman @GlassmanDS]

@Arsenal 🙌

[Arsenal @Arsenal]

The Arsenal. Your Premier League champions.

[Daniel Glassman @GlassmanDS]

@stusfootyflash What a moment! I remember it very well

[Daniel Glassman @GlassmanDS]

@DrAsifQasim @philmoss1 @Cambridge_Uni Very sad to read this. He was such a great teacher

[Daniel Glassman @GlassmanDS]

@Wisdom_HQ Don’t put chocolate in the fridge

[Daniel Glassman @GlassmanDS]

@GeoMetric_9 @grok what do you think of this chart and CRV prediction for end 2026

[Daniel Glassman @GlassmanDS]

@Arsenal I was there

[Daniel Glassman @GlassmanDS]

@Arsenal Leo, Leo, Leo! What a player 🙌

[Daniel Glassman @GlassmanDS]

@1968Tv My dad was at that match

[Daniel Glassman @GlassmanDS]

https://t.co/lrPE3ww8EB

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy

🔗 https://t.co/AhLkGTyaxc

👉🏻 Allocation to 5 further years of AIT reduced subsequent distant recurrence rates by about a quarter
👉🏻 The absolute further recurrence reduction from 5 further years of AIT appeared greater for women with node-positive than node-negative disease
👉🏻 1·2% excess 5-year incidence of reported bone fracture
@OncoAlert #OncoAlertAF @TheLancetOncol

[ABS @ABSGBI]

New guidance on pregnancy and breast cancer is available on the ABS Information Hub. This evidence-based guidance provides recommendations to support the treatment of patients with pregnancy associated breast cancer. Access the guidance here: https://t.co/1rI79493Zs

[ABS @ABSGBI]

The ABS has published guidance on the management of phyllodes tumours of the breast, which provides easily accessible evidence and recommendations for all clinicians managing patients with phyllodes tumours. Find out more: https://t.co/OaT0LPbaE0

[Daniel Glassman @GlassmanDS]

https://t.co/1pkqnbLiCH

[Elvina Almuradova @Dr_ElvinaA]

Important!
ASTER 70s trial in women ≥70y with ER+, HER2– breast cancer deemed high-risk by genomic signature (GGI) showed no OS benefit from adding chemo to hormonotherapy.

8y OS: 72.7% vs 68.3% (HR 0.83; p=0.21)
Toxicity: G3+ AEs 34% vs 9%
👉 More toxicity, no survival gain!
#BreastCancer #Oncology #ClinicalTrials #GeriatricOncology @oncoalert
@TheLancet @Larvol @onder_haka2124

[Daniel Glassman @GlassmanDS]

https://t.co/L7G3Y4ovCr

[Daniel Glassman @GlassmanDS]

@Neil_J_Smart @Dukes_Club ❤️

[Daniel Glassman @GlassmanDS]

@Mind_Essentials ❤️